Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETD001 in cystic fibrosis
NCT06478706Phase 2Completed
- Sponsor
- Enterprise Therapeutics
- Start
- Jun 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of ETD001 in cystic fibrosis (CF), sponsored by Enterprise Therapeutics. Started Jun 2024; status: completed.
02
Drugs
ETD001
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT06478706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06478706.